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Abstract Previous studies suggest a role for the plasminogen or 
fibrinolytic system in the activation of latent-transforming 
growth p (L-TGFP) into active TGFp. In the present study, 
the anti-apoptotic activity of TGFP on cultured vascular smooth 
muscle cells (SMC) isolated from the aorta of transgenic mice 
with single inactivation of genes encoding the tissue-type 
plasminogen activator (t-PA - / -) , urokinase-type plasminogen 
activator (u-PA - / -), urokinase receptor (u-PAR / ) or plasmi-
nogen (Pig - / - ) genes was examined. Latent-TGFp inhibited 
serum deprivation-induced apoptosis of SMC isolated from wild-
type and t-PA / mice but failed to reduce apoptosis of SMC 
isolated from u-PA - / - , u-PAR / or Pig / mice. Active 
TGFP, however, was able to inhibit serum deprivation-induced 
apoptosis of these 5 cell types, indicating that u-PA and/or 
plasmin were involved in the activation of L-TGFp. The anti-
apoptotic effect of L-TGFB could not be evoked by addition of 
exogenous t-PA to u-PA ' cells, but was revealed by addition 
of exogenous u-PA or plasmin. This effect was dependent on the 
catalytic activity of plasmin as revealed by the dose-dependent 
inhibition of aprotinin or epsilon aminocaproic acid (EACA). 
These results therefore indicate that, at least in vitro, u-PA-
mediated plasmin, through the generation of active TGFP from 
L-TGFP, is required for the anti-apoptotic activity of TGFP on 
SMC. 
© 1997 Federation of European Biochemical Societies. 
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TGFp must be released in order to bind a cellular receptor 
and elicit a biological response [20,21]. Activation of latent-
TGFP in co-cultures of endothelial cells and SMC [22,23] is 
mediated by plasmin which cleaves of the aminoterminal pro-
peptide from L-TGFP [23-27]. Recently, evidence has been 
provided that binding of u-PA to the urokinase receptor (u-
PAR) is required for plasmin-dependent conversion of latent-
TGFP [27]. This study and other recent investigations sug-
gested that the fibrinolytic system may play an important 
role in cell proliferation and/or migration during atheroscle-
rosis [28,29]. Indeed, several authors described both a mito-
genic and a chemotactic effect of the tissue-type plasminogen 
activator (t-PA) and of u-PA for several cell types including 
vascular smooth muscle cells [30-34]. Notably, vascular SMCs 
express u-PA and t-PA during mitogenesis and migration in 
vitro and in vivo following vascular injury [32,35-37]. A role 
for u-PA in SMC migration in vascular wound healing and 
arterial neointima formation after injury was recently demon-
strated by recent gene transfer and gene targeting studies in 
mice deficient for t-PA, u-PA, u-PAR and plasminogen (Pig) 
[28,34,38] which provided direct genetic evidence for a signifi-
cant role of fibrinolytic enzymes in this process [28,34,38]. 
Because of this close interaction between TGFP and the 
fibrinolytic system, this study was designed to investigate the 
activation of L-TGFP and its apoptotic effect on aortic SMC 
isolated from mice deficient in t-PA, u-PA, plasminogen and 
u-PAR. 
1. Introduction 
Apoptosis is a ubiquitous, evolutionarily conserved, phys-
iological mechanism of cell death regulating tissue mass and 
cyto-architecture in many tissues [1]. Cell death is also prom-
inent in human atherosclerotic plaques with areas of 'necrosis' 
being present in more than 80% of primary lesions [2-A]. Cell 
death has also been detected in animals models of atheroscle-
rosis [5-7] and after balloon injury in animals [8,9]. The mech-
anisms triggering apoptosis in atherosclerotic lesions remain 
unknown. Several authors have proposed that growth factors 
and cytokines produced by macrophages and lymphocytes 
[10,11] contribute to apoptosis of vascular smooth muscle cells 
(SMC) during atherogenesis, a hypothesis that has been un-
derscored by observations that some of these molecules pro-
mote apoptosis of SMC [4,12,13]. 
Transforming growth factor P (TGFP) is a potent inhibitor 
of endothelial and smooth muscle cell proliferation, migration 
and protease synthesis [14-19]. It is secreted by multiple cell 
types in a latent pro-form (latent-TGFP), from which mature 
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2. Materials and methods 
2.1. Animals 
Homozygous t-PA -/ -, u-PA -/ -, Pig -/ - and u-PAR-/- mice were 
obtained and characterized as described previously [28,39,40]. 
2.2. Isolation and culture of SMC 
SMC were isolated as described previously [41]. Briefly, media frag-
ments of the aorta were incubated for 16 h at 37°C in Dulbecco's 
modified Eagle medium (DMEM) containing 0.15% collagenase, 5% 
fetal calf serum (FCS), penicillin (100 IU/ml), streptomycin (100 fig/ 
ml) and glutamine (4 mM). After incubation, SMCs were sedimented 
by gentle centrifugation (400 Xg; 10 min), resuspended in 
DMEM+10% FCS and grown at 37°C in a humidified atmosphere 
of 5% C02 in air. Culture medium (DMEM+10% FCS) was changed 
every 3 days and a confluent SMC monolayer was obtained after 
about 7 days. Cells were routinely used from the third to the sixth 
passage. 
2.3. Expression of TGFfi by SMC 
Levels of active TGFp in the conditioned media were determined 
with a specific ELISA (R&D, Abingdon, UK). Under these experi-
mental conditions, the assay did not detect latent-TGFp\ 
2.4. Measurement of apoptosis 
SMC were seeded in 35 mm Petri dishes (5X105 cells/well) in 
DMEM+10% FCS and grown to confluence for 3 days. Culture me-
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dium was then aspirated, cells were rinsed and fresh medium+0.1% 
FCS was added in the presence of saline, latent-TGFp, TGFp (R&D, 
Abingdon, UK), plasmin, u-PA, t-PA, or plasmin inhibitors (epsilon 
aminocaproic acid: EACA or aprotinin) (Sigma Chemical Co., St. 
Louis, MO). Twenty-four hours later, apoptosis was measured with 
a photometric enzyme immunoassay (cell detection ELISA, Boeh-
ringer Mannheim, Mannheim, Germany) for the quantitative detec-
tion of cytoplasmic histone-associated DNA fragments (mono- and 
oligonucleosomes). Apoptosis was expressed as mean number of oli-
gonucleosomes/105 cells ±S.D. Results were from 3 different experi-
ments performed in triplicate. 
3. Results 
When added to growth-arrested aortic SMCs isolated from 
wild-type, t -PA - / - , u - P A - / - , u -PAR - / - or plasminogen-/-
mice, FCS depletion resulted in a dose-dependent pro-apop-
totic eifect (Fig. 1). As shown in Fig. 2A, the addition of 
active TGFp to wild-type or any mutant SMC dose-depend-
ently inhibited apoptotic cell death induced by FCS depletion 
with an IC50 value (dose which inhibited 50% of the pro-
apoptotic activity of 0.1% FCS) around 1 ng/ml. When added 
to growth-arrested aortic SMCs isolated from wild-type mice 
or t - P A - / - mice, L-TGFp also exhibited a dose-dependent 
anti-apoptotic activity (Fig. 2B). In contrast, L-TGFP failed 
to reduce apoptotic cell death when added to SMC isolated 
from u - P A - / - , u -PAR - / - or plasminogen-/- mice (Fig. 2B). 
These results indicate that both plasmin and u-PA are impor-
tant for activation of L-TGFp. 
The importance of plasmin and u-PA in the activation of L-
TGFP was further emphasized by the observation that addi-
tion of u-PA to u - P A - / - SMC diminished the pro-apoptotic 
activity of 0.1% FCS (Fig. 3). The inhibitory activity of L-
TGFP also occurred when plasmin but not exogenous t-PA 
was added. The dose-dependent inhibitory effect of plasmin 






Fig. 1. Serum-induced apoptosis of SMCs isolated from transgenic 
mice. Confluent monolayers of SMCs isolated from wild-type (•), 
t-PA-/- (■), u-PA-/- ( A ) , U - P A R - / - ( T ) or Pig-/ - (♦) mice, 
cultured in 35 mm dishes were incubated for 24 h at 37°C in 
DMEM containing increasing concentrations of FCS. Apoptosis 
was measured with an ELISA kit as described under Section 2 and 
expressed as mean numbers of oligonucleosomes/10B cells ±S.D. 





























Fig. 2. Effect of L-TGFp or TGFP on serum-induced apoptosis of 
SMCs. Confluent monolayers of SMCs isolated from wild-type (•), 
t-PA"/- (■), u-PA-/- ( A ) , U - P A R - / - ( T ) or Pig-/- (♦) mice, 
cultured in 35 mm dishes were incubated for 24 h at 37°C in 
DMEM containing 0.1% FCS and increasing concentrations of 
TGFp (A) or L-TGFp (B). Apoptosis was measured with an ELISA 
kit as described under Section 2 and expressed as mean numbers of 
oligonucleosomes/105 cells ± S.D. (n = 6). 
mediated the conversion of L-TGFP into active-TGFP (Fig. 
4). Moreover, the plasmin inhibitors were only effective when 
L-TGFP but not TGFp was added to the culture medium 
(Fig. 4). Quantitative determination of active TGFP revealed 
that u -PA - / - SMC were only able to convert L-TGFp to 
active TGFP when catalytically-active u-PA or plasmin were 
added, since both EACA and aprotinin blocked this conver-
sion (Fig. 5). 
4. Discussion 
Although vascular SMC accumulation is considered a key 
event in atherogenesis, specific regulatory mechanisms for cell 
proliferation and migration in the arterial wall are still poorly 
characterized. Cell death in human atherectomy and endarter-
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Fig. 3. Effect of u-PA on the apoptotic activity of FCS. Confluent 
SMCs from u-PA_/" mice were cultured for 24 h in DMEM+FCS 
(0.1%) in the presence of saline, murine u-PA (100 ng/ml), TGFp 
(100 nM), L-TGFp (100 nM) alone or associated with t-PA (100 
ng/ml), plasmin (100 ng/ml) or u-PA (100 ng/ml). Apoptosis was 
then measured with an ELISA kit as described under Section 2 and 
expressed as mean numbers of oligonucleosomes/105 cells ±S.D. 
(n = 6). 
ectomy specimens [2-4] and in animal models of vascular in-
jury [5-7], may be a key feature that influences the size and 
stability of vessel wall lesions. 
In vitro studies have identified several growth factors and 
cytokines that regulate apoptosis of vascular SMCs. Along 
with platelet derived growth factor-BB and insulin growth 
factor-1, several cytokines such as interferon-y, tumor ne-
crosis-oc and interleukin-lp are now considered to be likely 
candidates [4,13]. 
Although TGFP has opposite effects on proliferation versus 
migration of SMC [16,17,42,43], the precise molecular mech-
anisms for this dual role remain largely undefined. These dif-
ferent activities of TGFP have been tentatively attributed to a 
decrease of cell-mediated proteolysis and the subsequent dep-
osition of a new basement membrane and formation of junc-
tional complexes between cells [16,18]. 
The present study demonstrates that TGFP may result in 
SMC accumulation via a potent inhibitory effect on SMC 
apoptosis. Although the precise mechanism needs to be fur-
ther defined, this effect may relate to the ability of TGFP to 
increase intracellular cAMP levels [42]. Indeed, several studies 
have indicated a link between decreased apoptosis and in-
creased intracellular cAMP levels [4]. 
A significant role by the fibrinolytic system in the develop-
ment of arterial neointima formation and atherosclerotic le-
sions has been recently suggested by targeted gene manipula-
tion of t-PA, u-PA, PAI-1, u-PAR and plasminogen 
[28,34,38,44]. Moreover, in a recent study, using SMC isolated 
from these transgenic animals, we provided direct evidence 
that u-PA and t-PA are implicated in SMC migration and 
growth induced by bFGF and PDGF-BB, respectively [45]. 
It has been demonstrated that plasmin may activate latent-
TGFP [24] in particular when u-PA was bound to its cellular 
receptor [27,43]. Our data that u-PA-deficient SMC were un-
able to convert latent-TGFp into active TGFp confirm and 
extend these observations. Moreover, u-PA, through its ability 
to generate plasmin, tightly controls the generation of active 







Fig. 4. Effect of plasmin inhibitors on the anti-apoptotic effect of L-
TGFp. Confluent SMCs from wild-type mice were cultured for 24 h 
in DMEM+FCS (0.1%) in the presence of L-TGFP (100 ng/ml) (full 
symbols) or TGFP (100 ng/ml) (empty symbols) and increasing con-
centrations of EACA (squares) or aprotinin (circles). Apoptosis was 
then measured with an ELISA kit as described under Section 2 and 
expressed as mean numbers of oligonucleosomes/10B cells ±S.D. 





u-PA - + - + + + 
L-TGFP " - + + + + 
Aprotinin - - - - + -
EACA - - - - - + 
Fig. 5. Expression of TGFP by SMC. Confluent SMC from u-
PA~/" mice were incubated in DMEM+0.5% FCS in the presence 
of murine u-PA (100 ng/ml), L-TGFP (100 ng/ml), aprotinin (10 
uM) or EACA (10 |iM) as indicated. After 24 h, the amount of 
TGFP present in the culture medium was quantified as described 
under Section 2. Results are expressed as mean ± S.D. (n = 6). 
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expression of PAI-1 might contribute to a negative feedback 
loop in which increased u-PA expression by b F G F is counter-
acted by increased PAI-1 expression. 
Our studies demonstrate an important modulatory role for 
u-PAR in the anti-apoptotic activity of L-TGF(3. SMC iso-
lated from u-PAR-deficient mice did not respond to L-TGFP 
and antibodies to u-PAR, as well as aprotinin and EACA, 
were also able to inhibit the anti-apoptotic activity of L-
TGF(3 (not shown), suggesting that u -PAR may modulate 
the anti-apoptotic activity of L-TGFP in a plasmin-independ-
ent fashion. In our study, PAI-1 and oel-antitrypsin also 
showed an effect on the inhibitory effect of L - T G F p with 
regard to the pro-apoptotic activity of 0 .1% FCS (not shown) 
therefore confirming that, even when bound on its cell surface 
receptor, u-PA needs to be catalytically active to generate 
active T G F P from L-TGFp. 
These results therefore indicate that, at least in vitro, u-PA-
mediated plasmin, through its role in the generation of T G F P 
from L-TGFP is required for the control of the anti-apoptotic 
activity of T G F P on SMC and provides direct genetic evi-
dence for a causal role of u-PA in the regulation of the activ-
ity of T G F P . 
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